Emerging treatment options for extraintestinal manifestations in IBD

被引:67
作者
Greuter, Thomas [2 ,3 ]
Rieder, Florian [4 ]
Kucharzik, Torsten [5 ]
Peyrin-Biroulet, Laurent [6 ]
Schoepfer, Alain M. [7 ,8 ]
Rubin, David T. [9 ]
Vavricka, Stephan R. [1 ,2 ]
机构
[1] Gastroenterol & Hepatol Ctr, Zurich, Switzerland
[2] Univ Hosp Zurich, Dept Gastroenterol & Hepatol, Zurich, Switzerland
[3] GZO Zurich Reg Hlth Ctr, Dept Internal Med, Wetzikon, Switzerland
[4] Cleveland Clin, Digest Dis & Surg Inst, Div Gastroenterol Hepatol & Nutr, Cleveland, OH 44106 USA
[5] Klinikum Lueneburg, Div Gastroenterol & Hepatol, Luneburg, Germany
[6] Univ Henri Poincare 1, Univ Hosp Nancy, Dept Hepatogastroenterol, Inserm U954, Vandoeuvre Les Nancy, France
[7] Univ Hosp Lausanne CHUV, Div Gastroenterol & Hepatol, Lausanne, Switzerland
[8] Univ Lausanne, Lausanne, Switzerland
[9] Univ Chicago, Ctr Inflammatory Bowel Dis, Chicago, IL 60637 USA
基金
瑞士国家科学基金会;
关键词
arthritis; IBD clinical; TNF;
D O I
10.1136/gutjnl-2020-322129
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Extraintestinal manifestations (EIMs) are frequently observed in IBDs and contribute considerably to morbidity and mortality. They have long been considered a difficult to treat entity due to limited therapy options, but the increasing use of anti-tumour necrosis factors has dramatically changed the therapeutic approach to EIM in recent years. Newly emerging therapies such as JAK inhibitors and anti-interleukin 12/23 will further shape the available armamentarium. Clinicians dealing with EIMs in everyday IBD practice may be puzzled by the numerous available biological agents and small molecules, their efficacy for EIMs and their potential off-label indications. Current guidelines on EIMs in IBD do not include treatment algorithms to help practitioners in the treatment decision-making process. Herein, we summarise knowledge on emerging biological treatment options and small molecules for EIMs, highlight current research gaps, provide therapeutic algorithms for EIM management and shed light on future strategies in the context of IBD-related EIMs.
引用
收藏
页码:796 / 802
页数:7
相关论文
共 86 条
  • [81] Expression Patterns of TNFα, MAdCAM1, and STAT3 in Intestinal and Skin Manifestations of Inflammatory Bowel Disease
    Vavricka, Stephan R.
    Galvan, Jose A.
    Dawson, Heather
    Soltermann, Alex
    Biedermann, Luc
    Scharl, Michael
    Schoepfer, Alain M.
    Rogler, Gerhard
    Vavricka, Mareike B. Prinz
    Terracciano, Luigi
    Navarini, Alexander
    Zlobec, Inti
    Lugli, Alessandro
    Greuter, Thomas
    [J]. JOURNAL OF CROHNS & COLITIS, 2018, 12 (03) : 347 - 354
  • [82] Anti-TNF Treatment for Extraintestinal Manifestations of Inflammatory Bowel Disease in the Swiss IBD Cohort Study
    Vavricka, Stephan R.
    Gubler, Martin
    Gantenbein, Claudine
    Spoerri, Muriel
    Froehlich, Florian
    Seibold, Frank
    Protic, Marijana
    Michetti, Pierre
    Straumann, Alex
    Fournier, Nicolas
    Juillerat, Pascal
    Biedermann, Luc
    Zeitz, Jonas
    Misselwitz, Benjamin
    Scharl, Michael
    Heinrich, Henriette
    Manser, Christine N.
    Safroneeva, Ekaterina
    Ali, Raja Affendi Raja
    Rogler, Gerhard
    Schoepfer, Alain M.
    Greuter, Thomas
    [J]. INFLAMMATORY BOWEL DISEASES, 2017, 23 (07) : 1174 - 1181
  • [83] Extraintestinal Manifestations of Inflammatory Bowel Disease
    Vavricka, Stephan R.
    Schoepfer, Alain
    Scharl, Michael
    Lakatos, Peter L.
    Navarini, Alexander
    Rogler, Gerhard
    [J]. INFLAMMATORY BOWEL DISEASES, 2015, 21 (08) : 1982 - 1992
  • [84] Frequency and Risk Factors for Extraintestinal Manifestations in the Swiss Inflammatory Bowel Disease Cohort
    Vavricka, Stephan R.
    Brun, Lionel
    Ballabeni, Pierluigi
    Pittet, Valerie
    Vavricka, Bettina Mareike Prinz
    Zeitz, Jonas
    Rogler, Gerhard
    Schoepfer, Alain M.
    [J]. AMERICAN JOURNAL OF GASTROENTEROLOGY, 2011, 106 (01) : 110 - 119
  • [85] Immune-related systemic manifestations of inflammatory bowel disease - A prospective study of 792 patients
    Veloso, FT
    Carvalho, J
    Magro, F
    [J]. JOURNAL OF CLINICAL GASTROENTEROLOGY, 1996, 23 (01) : 29 - 34
  • [86] Filgotinib (GLPG0634/GS-6034), an oral JAK1 selective inhibitor, is effective in combination with methotrexate (MTX) in patients with active rheumatoid arthritis and insufficient response to MTX: results from a randomised, dose-finding study (DARWIN 1)
    Westhovens, R.
    Taylor, P. C.
    Alten, R.
    Pavlova, D.
    Enriquez-Sosa, F.
    Mazur, M.
    Greenwald, M.
    Van der Aa, A.
    Vanhoutte, F.
    Tasset, C.
    Harrison, P.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2017, 76 (06) : 998 - 1008